Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

Juleen Gayed, Oyeniyi Diya, Francine S. Lowry,Xia Xu, Vishva Bangad,Federico Mensa,Jing Zou,Xuping Xie,Yanping Hu,Claire Lu,Mark Cutler,Todd Belanger,David Cooper,Kenneth Koury,Annaliesa S. Anderson,Ozlem Tureci,Ugur Sahin,Kena A. Swanson,Kayvon Modjarrad,Alejandra Gurtman,Nicholas Kitchin

Vaccines（2024）

引用 0|浏览27

暂无评分

关键词

BNT162b2,COVID-19,SARS-CoV-2,vaccine,variant-adapted,booster,Omicron,XBB.1.5

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要